Compared with another Gpr109a agonist, the antiatherosclerotic drug niacin, which has been used clinically for more than 30 years, has limited its application due to its side effects such as skin flushing,[17, 53] 3‐HB maybe a promising option for long‐term treatment of atherosclerosis. This evidence concerns the gene HCAR2 and atherosclerosis.